Zomedica Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ZOM American 8731 http://www.zomedica.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zomedica Corp

Zomedica Appoints New Chief Financial Officer - Mar 17th, 2023 10:30 am
Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity - Revenue up 361% from 2021 through combination of acquisitions and organic growth - Mar 15th, 2023 8:45 pm
Zomedica to Host Fourth Quarter and Fiscal Year 2022 Financial Results Call on March 15 - Mar 8th, 2023 11:30 am
Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022 - Feb 9th, 2023 11:30 am
Zomedica Interview To Air on Bloomberg U.S. on the RedChip Money Report(R) - Feb 8th, 2023 9:15 pm
RedChip CEO Dave Gentry Invited to Join Forbes Business Council - Jan 25th, 2023 1:00 pm
Zomedica to Participate in the Lytham Partners Investor Select Conference - Jan 24th, 2023 11:00 am
Zomedica to Take Control of New Assay Development and Manufacturing of TRUFORMA Product Line through Long-Term Licensing Agreement with Qorvo Biotechnologies - Jan 18th, 2023 11:00 am
Sidoti's January Micro-Cap Conference - Jan 17th, 2023 3:00 pm
Zomedica Expands Relationship with Structured Medical Products and Begins Commercializing VetGuardian Wireless Monitors - Jan 17th, 2023 11:00 am
Zomedica to Present at Sidoti Virtual Investor Conference January 18-19 - Jan 11th, 2023 11:00 am
Zomedica CEO Interview with Wall Street Analyzer Updates Company Progress and Plans - Dec 15th, 2022 11:30 am
Zomedica Announces Third Quarter 2022 Financial Results: $4.78 Million Revenue; 75% Gross Margin & $158.49 Million in Cash, Cash Equivalents, and Available-For-Sale Securities - Nov 14th, 2022 9:20 pm
Zomedica to Present at LD Micro Main Event XV Conference - Oct 18th, 2022 10:30 am
Zomedica To Present at Dawson James Securities 7th Annual Small Cap Growth Conference - Sep 28th, 2022 10:30 am
Zomedica Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform - Sep 13th, 2022 10:30 am
Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference - Sep 12th, 2022 10:30 am
Zomedica Announces Designation of PulseVet® System as the Official Shock Wave Therapy of the National Cutting Horse Association - Sep 6th, 2022 10:30 am
Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors - Aug 23rd, 2022 10:30 am
Zomedica Announces Second Quarter 2022 Financial Results of $4.2 Million of Revenue; 71% Gross Margin & $186.8 Million in Cash; Revenue up 51% from 2021 Combined Revenues - Aug 15th, 2022 9:20 pm